| Literature DB >> 16788767 |
Isabel Martínez-Gras1, Janet Hoenicka, Guillermo Ponce, Roberto Rodríguez-Jiménez, Miguel Angel Jiménez-Arriero, Elena Pérez-Hernandez, Israel Ampuero, Jose Antonio Ramos-Atance, Tomas Palomo, Gabriel Rubio.
Abstract
The cannabinoid receptor 1 gene (CNR1) has been associated with addictive disorders and schizophrenia in different studies. We have compared the frequencies of the alleles for the 3'-UTR CNR1 microsatellite in a sample of 113 Spanish schizophrenic patients, including 68 with comorbid substance abuse, and 111 healthy controls. We report that the frequency of the allele 4 of this microsatellite is significantly lower in schizophrenia patients when compared with controls (chi(2) = 7.858; df 1; P = 0.005). No differences have been found with respect to substance abuse.Thus, the allele 4 represents, in our sample, a protective factor against schizophrenia (odds ratio 0.468, 95% confidence interval (CI) 0.27-0.79). The population attributable genetic risk for the allele 4 absence is 30% (95% CI = 17-41%) and the attributable risk for the allele 4 absence in those with schizophrenia is 53% (95% CI = 20-73%). Our results suggest that, independent of substance abuse, differences in the cannabinoid system function could be involved in the vulnerability to schizophrenia in Spanish population.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16788767 DOI: 10.1007/s00406-006-0665-3
Source DB: PubMed Journal: Eur Arch Psychiatry Clin Neurosci ISSN: 0940-1334 Impact factor: 5.270